We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Significant Technological Challenges Remain for the Development of RNA-Based Therapeutics
News

Significant Technological Challenges Remain for the Development of RNA-Based Therapeutics

Significant Technological Challenges Remain for the Development of RNA-Based Therapeutics
News

Significant Technological Challenges Remain for the Development of RNA-Based Therapeutics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Significant Technological Challenges Remain for the Development of RNA-Based Therapeutics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Research and Markets has announced the addition of Progress in RNA-Based Therapeutics to their offering.

The field of nucleic acid-based therapeutics ranges from gene therapy technologies for replacing defective or missing genes to gene-blocking or gene-silencing technologies for preventing the expression of deleterious genes.

RNA-based therapeutics are a relatively new addition to the field, and this report focuses on three such technologies in this report: antisense oligonucleotides, RNA interference, and microRNAs.

In this Decision Resources report, these three RNA-based technologies are described, recent progress in RNA-based drug discovery and development is reviewed, and the activities of companies in the field are profiled.

RNA-based technologies include antisense oligonucleotides, RNA interference, and microRNA. Companies have been testing ASOs in the clinic for ten years, and one antisense product, fomivirsen (Isis Pharmaceuticals' Vitravene), is on the market.

Acuity Pharmaceuticals and Sirna Therapeutics initiated the first two human clinical trials of RNAi-based products in 2004; additional clinical trials are anticipated in 2005 and 2006.

Advertisement